Lord Abbett Health Care FundLHCSX
Type
Mutual fund
Peer group
Global equity
Net assets
$8.1M
Expense ratio
1.03%
1-year return
+16.7%
3 years, a year
+5.8%
5 years, a year
+2.7%
Holdings
64
What it aims to do.
The Funds investment objective is to seek long-term capital appreciation.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| LLY Eli Lilly & Co | 8.89% |
| JOBY AstraZeneca PLC | 4.73% |
| GILD Gilead Sciences Inc | 4.25% |
| JNJ Johnson & Johnson | 3.19% |
| NKTR Nektar Therapeutics | 3.17% |
| NTRA Natera Inc | 2.91% |
| TARS Tarsus Pharmaceuticals Inc | 2.83% |
| GH Guardant Health Inc | 2.63% |
| JOBY Argenx SE | 2.49% |
| JOBY Novartis AG | 2.46% |
More on LHCSX.
- LHCSX overview
- LHCSX holdings
- LHCSX risk
- LHCSX costs
- LHCSX money in and out
- LHCSX share classes
- Compare LHCSX with other funds
Returns after fees, from the fund's SEC filings up to Apr 2026. Past returns are not a promise. Not financial advice.